Applying risk assessment models in orthopaedic surgery: Overview of our clinical experience

Blood Coagulation and Fibrinolysis

Volumn 10, Issue 6 SUPPL. 2, 1999, Pages

  Gallus, A S ^a  

^a FLINDERS MEDICAL CENTRE   (Australia)

Author keywords

Deep vein thrombosis; Low molecular weight heparins; Orthopaedic surgery; Risk assessment models; Risk factors; Unfractionated heparin; Venous thromboembolism

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; ARDEPARIN; DALTEPARIN; DEXTRAN 70; ENOXAPARIN; HEPARIN; HIRUDIN; LEPIRUDIN; LOW MOLECULAR WEIGHT HEPARIN; NADROPARIN; TINZAPARIN; WARFARIN;

BLEEDING; COMPRESSION THERAPY; CONFERENCE PAPER; DEEP VEIN THROMBOSIS; EPIDURAL ANESTHESIA; HUMAN; JOINT SURGERY; LUNG EMBOLISM; ORAL DRUG ADMINISTRATION; ORTHOPEDIC SURGERY; PREOPERATIVE CARE; PRIORITY JOURNAL; REGIONAL ANESTHESIA; RISK ASSESSMENT; THROMBOEMBOLISM; TREATMENT PLANNING;

ANTICOAGULANTS; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; ORTHOPEDICS; PULMONARY EMBOLISM; RISK ASSESSMENT; VENOUS THROMBOSIS;

EID: 0032857901     PISSN: 09575235     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (50)

1. Clagett GP, Anderson FA, Heit J, Levine M, Wheeler HB. Prevention of venous thromboembolism. Chest 1995; 108: 312S-334S.
2. Lassen MR, Borris LC. Prevention in orthopedic surgery and trauma. In: Hull R, Pineo G (editors). Venous thromboembolism - an evidence-based atlas. Armonk, NJ: Futura Publishers, 1997; 209-215.
3. Demers C, Marcoux S, Ginsberg JS, Laroche F, Cloutier R, Poulin J. Incidence of venographically proven deep vein thrombosis after knee arthroscopy. Arch Int Med 1998; 158: 47-50.
4. Gallus AS, Salzman EW, Hirsh J. Prevention of venous thromboembolism. In: Colman RW, Hirsh J, Marder VJ (editors). Hemostasis and Thrombosis: Basic Principles and Clinical Practice. 3rd edition. Philadelphia: Lippincott, 1994; 1331-1345.
5. Sheppeard H, Henson J, Ward DJ. A clinicopathological study of fatal pulmonary embolism in a specialist orthopedic hospital. Arch Orthop Trauma Surg 1981; 99: 65.
6. Roberts TS, Nelson CL, Lowry Barnes C, Ferris EJ, Holder JC, Boone DW. The preoperative prevalence and postoperative incidence of thromboembolism in patients with hip fractures treated with dextran prophylaxis. Clin Orthop Related Res 1990; 255: 198-203.
7. Hefley WH Jr, Nelson CL, Puskarich-May CL. Effect of delayed admission to hospital on the preoperative prevalence of deep-vein thrombosis associated with fractures of the hip. J Bone Joint Surg (Am) 1996; 78: 581-583.
8. Eriksson BI, Ekman S, Kalebo P, Zachrisson B, Bach D, Close P. Prevention of deep-vein thrombosis after total hip replacement: direct thrombin inhibition with recombinant hirudin, CGP 39393. Lancet 1996; 347: 635-639.
9. Eriksson BI, Ekman S, Lindbratt S, Baur M, Bach D, Torholm C, et al. Prevention of thromboembolism with use of recombinant hirudin. J Bone Joint Surg (Am) 1997; 79: 326-333.
10. Eriksson BI, Wille-Jørgensen P, Kalebo P, Mouret P, Rosenscher N, Bosch P, et al. A comparison of recombinant hirudin with a low molecular weight heparin to prevent thromboembolic complications after total hip replacement. N Engl J Med 1997; 337: 1329-1335.
11. Santori FS, Vitullo A, Stopponi M, Santori N, Ghera S. Prophylaxis against deep-vein thrombosis after total hip replacement. Comparison of heparin and foot impulse pump. J Bone Joint Surg (Br) 1994; 76: 579-583.
12. Levine MN, Gent M, Hirsh J, Weitz J, Turpie AG, Powers P, et al. Ardeparin (low-molecular-weight heparin) vs graduated compression stockings for the prevention of venous thromboembolism. A randomized trial in patients undergoing knee surgery. Arch Int Med 1996; 156: 851-856.
13. Horlocker TT, Heit JA. Low molecular weight heparin: biochemistry, pharmacology, perioperative prophylaxis regimens, and guidelines for regional anaesthesia management. Anesthesia Analgesia 1997; 85: 874-885.
14. Wysowski DK, Talarico L, Bacsanyi J, Botstein P. Spinal and epidural hematoma and low-molecular-weight heparin. N Engl J Med 1998; 338: 1774.
15. Bergqvist D, Lindblad B, Matzsch T. Risk of combining low molecular weight heparin for thromboprophylaxis with epidural or spinal anesthesia. Semin Thromb Hemost 1993; 19: 147-151.
16. Weitz JI. Low-molecular-weight heparin. N Engl J Med 1998; 338:687-688.
17. Prins MH, Hirsh J. A comparison of general anesthesia and regional anesthesia as a risk factor for deep vein thrombosis following hip surgery: a critical review. Thromb Haemost 1990; 64:497-500.
18. Dauphin A, Raymer KE, Stanton EB, Fuller HD. Comparison with general anesthesia with and without lumbar epidural for total hip arthroplasty: effects of epidural block on hip arthroplasty. J Clin Anethesia 1997; 9:200-203.
19. Eskander MB, Limb D, Stone MH, Furlong AJ, Shardlow D, Stead D, et al. Sequential mechanical and pharmacological thromboprophylaxis in the surgery of hip fractures. A pilot study. Int Orthop 1997; 21:259-261.
20. Samama CM, Clergue F, Barre J, Montefiore A, Ill P, Samii K, et al. Low molecular weight heparin associated with spinal anaesthesia and gradual compression stockings in total hip replacement surgery. Br J Anaesthesia 1997; 78:660-665.
21. Leclerc JR, Geerts WH, Desjardin L, Laflamme GH, L'Esperance B, Demers C, et al. Prevention of venous thromboembolism after knee arthroplasty. A randomized, double-blind trial comparing enoxaparin with warfarin. Ann Int Med 1996; 124:619-626.
22. Kalodiki EPh, Hoppenstead DA, Nicolaides AN, Fareed J, Gill K, Regan F, et al. Deep venous thrombosis prophylaxis with low molecular weight heparin and elastic compresison in patients having total hip replacement. A randomised controlled trial. Int Angiol 1996; 15:162-168.
23. Colwell CW Jr, Spiro TE, Trowbridge AA, Morris BA, Kwaan HC, Blaha JD, et al. Use of enoxaparin, a low-molecular-weight heparin, and unfractionated heparin for the prevention of deep venous thrombosis after elective hip replacement. A clinical trial comparing efficacy and safety. Enoxaparin Clinical Trial Group. J Bone Joint Surg (Am) 1994; 76: 3-14.
24. Spiro TE, Johnson GJ, Christie MJ, Lyons RM, MacFarlane DE, Blasier RB, et al. Efficacy and safety of enoxaparin to prevent deep venous thrombosis after hip replacement surgery. Enoxaparin Clinical Trial Group. Ann Int Med 1994; 121: 81-89.
25. RD Heparin Arthroplasty Group. RD heparin compared with warfarin for prevention of venous thromboembolic disease following total hip or knee arthroplasty. J Bone Joint Surg (Am) 1994; 76: 1174-1185.
26. Turpie AGG, Levine M, Hirsh J. A randomized controlled trial of a low-molecular weight heparin (Enoxaparin) to prevent deep vein thrombosis in patients undergoing elective hip surgery. N Engl J Med 1986; 315: 925-929.
27. Planés A, Vochelle N, Fagola M, Bellaud M, Feret J, Salzard C, et al. Efficacy and safety of a perioperative enoxaparin regimen in total hip replacement under various anesthesias. Am J Surg 1991; 161: 525-531.
28. Kearon C, Hirsh J. Starting prophylaxis for venous thromboembolism postoperatively. Arch Int Med 1995; 155: 366-372.
29. Johnson R, Carmichael JHE, Almond HGA, Loynes RP. Deep venous thrombosis following Charnley arthroplasty. Clin Orthop Related Res 1978; 132: 24-30.
30. Sikorski JM, Hampson WG, Staddon GE. The natural history and aetiology of deep vein thrombosis after total hip replacement. J Bone Joint Surg (Br) 1981; 63: 171-177.
31. Pellegrini VD, Clement D, Lush-Ehmann C, Keller GS, McCollister Evarts C. Natural history of thromboembolic disease after total hip arthroplasty. Clin Orthop Related Res 1996; 333: 27-40.
32. Pellegrini VD, Langhans MJ, Totterman S, Marder VJ, Francis CW. Embolic complications of calf thrombosis following total hip arthroplasty. J Arthroplasty 1993; 8: 449-457.
33. Agnelli G, Ranucci V, Veschi F, Rinonapoli E, Lupatelli L, Nenci GG. Clinical outcome of orthopaedic patients with negative lower limb venography at discharge. Thromb Haemost 1995; 74: 1042-1044.
34. Ricotta S, Iorio A, Parise P, Nenci GG, Agnelli G. Post discharge clinically overt venous thromboembolism in orthopaedic surgery patients with negative venography - an overview analysis. Thromb Haemost 1996; 76: 887-892.
35. Planés A, Vochelle N, Darmon J-Y, Fagola M, Bellaud M, Huet Y. Risk of deep-venous thrombosis after hospital discharge in patients having undergone total hip replacement: double-blind randomised comparison of enoxaparin versus placebo. Lancet 1996; 348: 224-228.
36. Bergqvist D, Benoni G, Bjorgell O, Fredin H, Hedlund U, Nicolas S, et al. Low-molecular-weight heparin (enoxaparin) as prophylaxis against venous thromboembolism after total hip replacement. N Engl J Med 1996; 335: 696-700.
37. Dahl OE, Andreassen G, Aspelin T, Mathieson P, Nyhus S, Abdelnoor M, et al. Prolonged thromboprophylaxis following hip replacement surgery - results of a double-blind, prospective, randomized, placebo-controlled study with dalteparin (fragmin). Thromb Haemost 1997; 77: 26-31.
38. Lassen MR, Borris LC, Anderson BS, Jensen HP, Skejo Bro HP, Andersen G, et al. Efficacy and safety of prolonged thromboprophylaxis with a low molecular weight heparin (dalteparin) after total hip arthroplasty - the Danish prolonged prophylaxis (DaPP) study. Thromb Res 1998; 89: 281-287.
39. Alatri A, Iorio A, Agnelli G. Choice of end-points in assessing the efficacy of post-discharge prophylaxis for venous thromboembolism. Thromb Haemost 1998; 79: 234-234.
40. Leclerc JR, Gent M, Hirsh J, Geerts WH, Ginsberg JS. The incidence of symptomatic venous thromboembolism during and after prophylaxis with enoxaparin: a multi-institutional cohort study of patients who underwent hip or knee arthroplasty. Canadian Collaborative Group. Arch Int Med 1998; 158: 873-878.
41. Lieberman JR, Wollaeger J, Dorey F, Thomas BJ, Kilgus DJ, Grecula MJ, et al. The efficacy of prophylaxis with low-dose warfarin for prevention of pulmonary embolism following total hip arthroplasty. J Bone Joint Surg (Am) 1997; 79: 319-325.
42. Francis CW, Pellegrini VD, Leibert KM, Totterman S, Azodo MV, Harris CM, et al. Comparison of two warfarin regimens in the prevention of venous thrombosis following total knee replacement. Thromb Haemost 1996; 75: 706-711.
43. Hull R, Raskob G, Pineo G, Rosenbloom D, Evans W, Mallory T, et al. A comparison of subcutaneous low-molecular-weight heparin with warfarin sodium for prophylaxis against deep-vein thrombosis after hip or knee implantation. N Engl J Med 1993; 329: 1370-1376.
44. Hamulyak K, Lensing AW, van der Meer J, Smid WM, van Ooy A, Hoek JA. Subcutaneous low-molecular weight heparin or oral anticoagulants for the prevention of deep-vein thrombosis in elective hip or knee replacement? Fraxiparin Oral Anticoagulant Study Group. Thromb Haemost 1995; 74: 1428-1431.
45. Francis CW, Pellegrini VD, Totterman S, Boyd AD Jr, Marder VJ, Liebert KM, et al. Prevention of deep-vein thrombosis after total hip arthroplasty. Comparison of warfarin and dalteparin. J Bone Joint Surg (Am) 1997; 79: 1365-1372.
46. Janku GV, Paiement GD, Green HD. Prevention of venous thromboembolism in orthopaedics in the United States. Clin Orthop Related Res 1996; 325: 313-321.
47. Williams HR, Macdonald DA. Audit of thromboembolic prophylaxis in hip and knee surgery. Ann Royal Coll Surg Engl 1997; 79: 55-57.
48. Todd CJ, Freemen CJ, Camilleri-Ferrante C, Palmer CR, Hyder A, Laxton CE, et al. Differences in mortality after fracture of the hip: the East Anglian audit. BMJ 1995; 310: 904-908.
49. Anderson FA, Wheeler HB, Goldberg RJ, Hosmer DW, Forcier A, Patwardhan NA. Changing clinical practice. Prospective study of the impact of continuing medical education and quality assurance programs on use of prophylaxis for venous thromboembolism. Arch Int Med 1994; 154: 669-677.
50. McNally MA, Cooke EA, Harding ML, Mollan RA. Attitudes to, and utilization of, low molecular weight heparins in joint replacement surgery. J Royal Coll Surg Edinburgh 1997; 42: 407-409.